nach oben

CNS Drugs

Erschienen in:

01.11.2011 | Review Article

Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia

verfasst von: Dr Maria J. Arranz, Margarita Rivera, Janet C. Munro

Erschienen in: CNS Drugs | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

This review presents the findings of pharmacogenetic studies exploring the influence of gene variants on antipsychotic treatment response, in terms of both symptom improvement and adverse effects, in patients with schizophrenia.

Despite numerous studies in the field, replicating findings across different cohorts that include subjects of different ethnic groups has been challenging. It is clear that non-genetic factors have an important contribution to antipsychotic treatment response. Differing clinical, demographic and environmental characteristics of the cohorts studied have added substantial complexity to the interpretation of the positive and negative findings of many studies.

Pharmacogenomic genome-wide investigations are beginning to yield interesting data although they have failed to replicate the most robust findings of candidate gene studies, and are limited by the sample size, especially given the need for studying homogeneous cohorts.

Most of the studies conducted on cohorts treated with single anti-psychotics have investigated clozapine, olanzapine or risperidone response. These studies have provided some of the most replicated associations with treatment efficacy. Serotonergic system gene variants are significantly associated with the efficacy of clozapine and risperidone, but may have less influence on the efficacy of olanzapine. Dopamine D₃ receptor polymorphisms have been more strongly associated with the efficacy of clozapine and olanzapine, and D₂ genetic variants with the efficacy of risperidone.

Serotonin influences the control of feeding behaviour and has been hypothesized to have a role in the development of antipsychotic-induced weight gain. Numerous studies have linked the serotonin receptor 2C (5-HT2C) −759-C/T polymorphism with weight gain. The leptin gene variant, −2548-G/A, has also been associated with weight gain in several studies. Pharmacogenetic studies support the role of cytochrome P450 enzymes and dopamine receptor variants in the development of antipsychotic-induced movement disorders, with a contribution of serotonergic receptors and other gene variants implicated in the mechanism of action of antipsychotics. Clozapine-induced agranulocytosis has been associated with polymorphisms in the major histocompatibility complex gene (HLA).

Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988 Jan; 23(1): 99–110PubMed

Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006 May; 21(5): 589–98PubMed

Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988 Sep; 153: 376–81PubMed

Vojvoda D, Grimmell K, Sernyak M. Monozygotic twins concordant for response to clozapine [letter]. Lancet 1996; 347(8993): 61PubMed

Horacek J, Libiger J, Hoschl C, et al. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 2001; 5(1): 71–3

Muller DJ, Schulze TG, Knapp M, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001 Nov; 104(5): 375–9PubMed

Mata I, Madoz V, Arranz MJ, et al. Olanzapine: concordant response in monozygotic twins with schizophrenia [letter]. Br J Psychiatry 2001 Jan; 178(1): 86PubMed

Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005 Dec; 15(4): 285–9PubMed

Wehmeier PM, Gebhardt S, Schmidtke J, et al. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005 Feb 28; 133(2–3): 273–6PubMed

10.

Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 2011 May 15; 187(1–2): 42–8PubMed

11.

Schennach-Wolff R, Jager M, Obermeier M, et al. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry 2010 Aug; 11(5): 729–38PubMed

12.

Giegling I, Drago A, Schafer M, et al. Interaction of halo-peridol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010 Jun; 44(8): 487–92PubMed

13.

Lipkovich IA, Deberdt W, Csernansky JG, et al. Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res 2009 Dec 30; 170(2–3): 161–7PubMed

14.

Jager M, Schmauss M, Laux G, et al. Early improvement as a predictor of remission and response in schizophrenia: rasults from a naturalistic study. Eur Psychiatry 2009 Dec; 24(8): 501–6PubMed

15.

Lin CH, Chou LS, Lin CH, et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007 Oct; 68(10): 1522–7PubMed

16.

Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007 Mar; 68(3): 352–60PubMed

17.

Brousse G, Meary A, Blanc O, et al. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Psychiatry Res 2010 Aug 30; 179(1): 12–8PubMed

18.

Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug 15; 31(6): 1330–6PubMed

19.

Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 9: 5–9PubMed

20.

Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: socio-demographics, premorbid and clinical variables. J Psychiatr Res 2007 Oct; 41(8): 659–66PubMed

21.

Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 2011 Feb; 125(2–3): 236–46PubMed

22.

Haro JM, Novick D, Suarez D, et al. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jul 1; 32(5): 1287–92PubMed

23.

Gunduz-Bruce H, McMeniman M, Robinson DG, et al. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 2005 Oct; 162(10): 1966–9PubMed

24.

Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005 Oct; 162(10): 1785–804PubMed

25.

Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007 Jan; 89(1–3): 129–39PubMed

26.

Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002 May; 63(5): 420–4PubMed

27.

Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993; 29(3): 365–9PubMed

28.

Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993 Mar; 54 Suppl. : 13–7PubMed

29.

Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004 Jul; 185: 18–24PubMed

30.

Pickar D, Owen Jr RR, Litman RE, et al. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994 Sep; 55 Suppl. B: 129–32PubMed

31.

Jalenques I, Tauveron I, Albuisson E, et al. Weight gain and clozapine. Encephale 1996 Oct; 22 Spec No 3: 77–9

32.

Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006 Apr; 26(2): 128–34PubMed

33.

Calarge CA, Ellingrod VL, Zimmerman B, et al. Leptin gene-2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet 2009 Dec; 19(6): 320–7PubMed

34.

Park YM, Chung YC, Lee SH, et al. Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006 Jun 5; 141(4): 394–7

35.

Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005 Apr 5; 134(1): 76–8

36.

Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009 Aug; 9(4): 234–41PubMed

37.

Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011 May; 128(1–3): 166–70PubMed

38.

Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007 Jan; 100(1): 4–22PubMed

39.

van der WJ, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003 Mar; 13(3): 169–72

40.

Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15(6): 469–94PubMed

41.

de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003 Feb; 27(1): 165–71PubMed

42.

Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003 Oct; 17(5): 517–38PubMed

43.

Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007 Jun 5; 12(8): 707–47PubMed

44.

Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999 Apr; 156(4): 544–9PubMed

45.

Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004 Aug; 161(8): 1324–33PubMed

46.

Yasui-Furukori N, Saito M, Nakagami T, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 Apr 16; 34(3): 537–40PubMed

47.

Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002 Jan; 63(1): 9–14PubMed

48.

Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008 Feb; 48(2): 157–65PubMed

49.

Frackiewicz EJ, Sramek JJ, Herrera JM, et al. Ethnicity and antipsychotic response. Ann Pharmacother 1997 Nov;31(11): 1360–9PubMed

50.

Tabatabaee M, Sharifi V, Alaghband-rad J, et al. Acute treatment response and its predictors in patients with first-episode psychosis in Iran. Australas Psychiatry 2008 Apr; 16(2): 125–9PubMed

51.

Joober R, Rouleau GA, Lal S, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 2005 Sep 1; 77(1): 35–41PubMed

52.

Arranz MJ, Munro J, Osborne S, et al. Difficulties in replication of results. Lancet 2000; 356: 1359–60PubMed

53.

Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007 Feb; 90(1–3): 86–96PubMed

54.

Eap CB, Bender S, Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004 Apr; 24(2): 214–9PubMed

55.

Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 Aug 16; 34(6): 1026–32PubMed

56.

Potkin SG, Basile VS, Jin Y, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003 Jan; 8(1): 109–13PubMed

57.

Hwang R, Shinkai T, De Luca V, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007 Sep; 21(7): 718–27PubMed

58.

Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005 Aug; 181(1): 179–87

59.

Hwang R, Shinkai T, Deluca V, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006 May; 16(4): 248–59PubMed

60.

Shaikh S, Collier DA, Sham P, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Gen 1996; 97: 714–9

61.

Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol 1999; 10(1): 17–20PubMed

62.

Zhao AL, Zhao JP, Zhang YH, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005 Nov; 115(11): 1539–47PubMed

63.

Zuo L, Luo X, Krystal JH, et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics 2009 Jun; 19(6): 437–46PubMed

64.

Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008 Oct; 9(10): 1429–36PubMed

65.

Souza RP, Romano-Silva MA, Lieberman JA, et al. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res 2010 Aug; 44(11): 700–6PubMed

66.

Mancama D, Arranz MJ, Munro J, et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 2002 Nov 29; 333(3): 207–11PubMed

67.

Yu YW, Tsai SJ, Yang KH, et al. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsycho-biology 2001; 43(2): 79–82

68.

Arranz MJ, Collier DA, Sodhi M, et al. Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet 1995; 346: 281–2PubMed

69.

Masellis M, Basile VS, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123–32PubMed

70.

Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61–6PubMed

71.

Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93–9PubMed

72.

Sodhi M, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169–72PubMed

73.

Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615–6PubMed

74.

Yu YWY, Tsai S-J, Lin C-H, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999; 10: 1231–3PubMed

75.

Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res 2010 Dec; 44(16): 1158–62PubMed

76.

Souza RP, De Luca V, Meltzer HY, et al. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol 2010 Jul; 13(6): 793–8PubMed

77.

Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004 Oct; 161(10): 1798–805PubMed

78.

Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002 Jun; 162(1): 18–23

79.

Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008 Mar 4; 23(4): 267–74PubMed

80.

Bishop JR, Ellingrod VL, Moline J, et al. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005 Sep 15; 77(2–3): 253–60PubMed

81.

Bozina N, Medved V, Kuzman MR, et al. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 2007 Sep; 21(7): 728–34PubMed

82.

Bozina N, Kuzman MR, Medved V, et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008 Jan; 42(2): 89–97PubMed

83.

Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol 2007 Oct; 27(5): 520–3PubMed

84.

Meary A, Brousse G, Jamain S, et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2008 Jun 5; 147B(4): 491–4PubMed

85.

Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008 Oct; 9(10): 1437–43PubMed

86.

Xu MQ, St Clair D, Feng GY, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008 Apr 10; 18(6): 449–57PubMed

87.

Du J, Zhang A, Wang L, et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2010 Jul; 24(7): 1115–20PubMed

88.

Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009 Mar; 10(3): 385–97PubMed

89.

Fijal BA, Kinon BJ, Kapur S, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009 Oct; 9(5): 311–8PubMed

90.

Lane HY, Lee CC, Chang YC, et al. Effects of dopamine D2 receptor Ser311 Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004 Dec; 7(4): 461–70PubMed

91.

Yamanouchi Y, Iwata N, Suzuki T, et al. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3(6): 356–61PubMed

92.

Xing Q, Qian X, Li H, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007 Oct; 10(5): 631–7PubMed

93.

Lane HY, Hsu SK, Liu YC, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005 Feb; 25(1): 6–11PubMed

94.

Wang L, Fang C, Zhang A, et al. The −1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008 Nov; 22(8): 904–9PubMed

95.

Lane HY, Chang YC, Chiu CC, et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002 Sep; 159(9): 1593–5PubMed

96.

Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008 Jan; 23(1): 61–7PubMed

97.

Liu BC, Zhang J, Wang L, et al. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics 2010 May; 11(5): 685–92PubMed

98.

Gu B, Wang L, Zhang AP, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008 Aug; 18(8): 721–7PubMed

99.

Lane HY, Lin CC, Huang CH, et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004 Mar 1; 67(1): 63–70PubMed

100.

Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007 Feb 27; 414(1): 1–4PubMed

101.

Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006 Oct; 7(7): 987–93PubMed

102.

Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 2008 Feb; 28(1): 64–8PubMed

103.

Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002 Oct; 72(4): 438–52PubMed

104.

Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005 Mar 7; 376(1): 1–4PubMed

105.

Schafer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001 May; 158(5): 802–4PubMed

106.

Kwon JS, Kim E, Kang DH, et al. Taq1 A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008 Dec; 18(12): 897–907PubMed

107.

Shen YC, Chen SF, Chen CH, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009 Mar; 43(6): 600–6PubMed

108.

Yasui-Furukori N, Saito M, Nakagami T, et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006 Mar; 30(2): 286–91PubMed

109.

Krebs MO, Guillin O, Bourdel MC, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000; 5(5): 558–62PubMed

110.

Hamdani N, Tabeze JP, Ramoz N, et al. The CNR 1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008 Jan; 18(1): 34–40PubMed

111.

Weickert TW, Goldberg TE, Mishara A, et al. Catechol-O-methyltransferase val 108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004 Nov 1; 56(9): 677–82PubMed

112.

Anttila S, Illi A, Kampman O, et al. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004 May; 14(5): 303–7PubMed

113.

Molero P, Ortuno F, Zalacain M, et al. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007 Dec; 7(6): 418–26PubMed

114.

Suzuki A, Kondo T, Mihara K, et al. The −141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001 Aug; 11(6): 545–50PubMed

115.

Vijayan NN, Bhaskaran S, Koshy LV, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population [letter]. Behav Brain Funct 2007; 3: 34PubMed

116.

Dahmen N, Muller MJ, Germeyer S, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophr Res 2001 Apr 15; 49(1–2): 223–5PubMed

117.

Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004 Jan 1; 124(1): 1–5

118.

Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005 Mar; 15(2): 143–51PubMed

119.

Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D-4 receptor and response to antipsychotic drugs. Psychopharmacology 1999; 141: 6–10PubMed

120.

Reynolds GP, Arranz B, Templeman LA, et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006 Oct; 163(10): 1826–9PubMed

121.

Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24: 141–6PubMed

122.

Hamdani N, Bonniere M, Ades J, et al. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005 Mar 22; 377(1): 69–74PubMed

123.

Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008; 8: 40PubMed

124.

Vazquez-Bourgon J, Arranz MJ, Mata I, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010 Feb 28; 175(3): 189–94PubMed

125.

Joober R, Benkelfat C, Lal S, et al. Association between the methylenetetrahydrofolate reductase 677C/T missense mutation and schizophrenia. Mol Psychiatry 2000; 5: 323–6PubMed

126.

Strous RD, Greenbaum L, Kanyas K, et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 2006 May 31; 1-13

127.

Kampman O, Anttila S, Illi A, et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004 Nov 15; 15(16): 2517–20PubMed

128.

Zai G, Muller DJ, Volavka J, et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006 Oct; 188(2): 171–82

129.

Shaikh S, Makoff A, Collier DA, et al. Dopamine D4 receptors: potential therapeutic implications in the treatment of schizophrenia. CNS Drugs 1997; 8: 1–11

130.

Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine [letter]. Lancet 1993 Jan 9; 341(8837): 116PubMed

131.

Rao PA, Pickar D, Gejman PV, et al. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994 Nov; 51(11): 912–7PubMed

132.

Rietschel M, Naber D, Oberlander H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996 Nov; 15(5): 491–6PubMed

133.

Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010 Jun; 10(3): 200–18PubMed

134.

Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217: 177–8PubMed

135.

Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008 Nov; 34(6): 1130–44PubMed

136.

Nothen MM, Rietschel M, Erdmann J, et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995 Sep 30; 346(8979): 908–9PubMed

137.

Rietschel M, Naber D, Fimmers R, et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997 May 27; 8(8): 1999–2003PubMed

138.

Malhotra AK, Goldman D, Ozaki N, et al. Clozapine response and the 5HT(2C) Cys(23)Ser polymorphism. Neuroreport 1996; 7(13): 2100–2PubMed

139.

Malhotra AK, Goldman D, Ozaki N, et al. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996 Aug; 153(8): 1092–4PubMed

140.

Masellis M, Basile VS, Meltzer HY, et al. Lack of association between the T-C267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001; 47: 49–58PubMed

141.

Masellis M, Paterson AD, Badri F, et al. Genetic variation of 5-HT2A receptor and response to clozapine [letter]. Lancet 1995 Oct 21; 346(8982): 1108PubMed

142.

Birkett JT, Arranz MJ, Munro J, et al. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000 Jun 26; 11(9): 2017–20PubMed

143.

Gutierrez B, Arranz MJ, Huezo-Diaz P, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 2002 Nov 1; 58(1): 93–7PubMed

144.

Arranz MJ, Bolonna AA, Munro J, et al. The serotonin transporter and clozapine response. Mol Psychiatry 2000; 5: 124–30PubMed

145.

Kaiser R, Tremblay PB, Schmider J, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001 Mar; 6(2): 179–85PubMed

146.

Bolonna AA, Arranz MJ, Munro J, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000; 280: 65–8PubMed

147.

Bolonna AA, Kerwin RW, Munro J, et al. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res 2001 Jan 15; 47(1): 99–103PubMed

148.

Tsai SJ, Wang YC, Yu Younger WY, et al. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001 Apr 15; 49(1–2): 53–8PubMed

149.

Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995; 39: 417–20PubMed

150.

Thomas P, Srivastava V, Singh A, et al. Correlates of response to olanzapine in a North Indian schizophrenia sample. Psychiatry Res 2008 Dec 15; 161(3): 275–83PubMed

151.

Itokawa M, Arinami T, Toru M. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J Pharmacol Sci 2010 Sep 16; 114(1): 1–5PubMed

152.

Xuan J, Zhao X, He G, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008 Jan; 33(2): 305–11PubMed

153.

Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006 Mar; 163(3): 529–31PubMed

154.

Zalsman G, Frisch A, Lev-Ran S, et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003 May; 13(3): 183–5PubMed

155.

Wei Z, Wang L, Xuan J, et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 Apr 30; 33(3): 547–51PubMed

156.

Natesan S, Reckless GE, Barlow KB, et al. Amisulpride the ‘atypical’ atypical antipsychotic: comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008 Oct; 105(1–3): 224–35PubMed

157.

Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009 Apr 30; 33(3): 470–4PubMed

158.

Lee HY, Kim DJ, Lee HJ, et al. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33(2): 276–80PubMed

159.

Muller DJ, De Luca V, Sicard T, et al. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005 Oct; 15(5): 525–31PubMed

160.

Gasso P, Mas S, Bernardo M, et al. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009 Dec; 9(6): 404–10PubMed

161.

Saiz PA, Susce MT, Clark DA, et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008 Mar; 23(2): 107–14PubMed

162.

Xu MQ, Xing QH, Zheng YL, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007 Sep; 68(9): 1358–67PubMed

163.

Liou YJ, Liao DL, Chen JY, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004; 5(3): 243–51PubMed

164.

Park SW, Lee JG, Kong BG, et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009 Aug; 63(4): 433–9PubMed

165.

Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009 May; 19(5): 317–28PubMed

166.

Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006 Feb; 16(2): 111–7

167.

Herken H, Erdal ME, Boke O, et al. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003 Mar; 18(2): 77–81PubMed

168.

Lai IC, Wang YC, Lin CC, et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005 Aug; 112(8): 1107–13PubMed

169.

Matsumoto C, Shinkai T, Hori H, et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004 Jun 30; 127(1–2): 1–7PubMed

170.

Lafuente A, Bernardo M, Mas S, et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and -141C Ins/ Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008 Nov 30; 161(2): 131–41PubMed

171.

Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000 Jul; 5(4): 410–7PubMed

172.

Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5(1): 60–9

173.

Fu Y, Fan CH, Deng HH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006 Mar; 27(3): 328–32PubMed

174.

Matsumoto C, Ohmori O, Shinkai T, et al. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004 Dec; 14(4): 209–13PubMed

175.

Tiwari AK, Deshpande SN, Lerer B, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007 Oct; 7(5): 305–11

176.

Schillevoort I, de Boer A, van der Weide J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002 Apr; 12(3): 235–40PubMed

177.

Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005 Jun 1; 75(1): 21–6

178.

Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49(4): 167–73PubMed

179.

Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D 6. Int Clin Psychopharmacol 2005 Mar; 20(2): 71–8PubMed

180.

de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005 Oct; 25(5): 448–56PubMed

181.

Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000 Dec; 56(9–10): 679–83PubMed

182.

Lohmann PL, Bagli M, Krauss H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003 Mar; 36(2): 73–8PubMed

183.

Inada T, Senoo H, Iijima Y, et al. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extra-pyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003 Sep; 13(3): 163–8PubMed

184.

Crescenti A, Mas S, Gasso P, et al. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extra-pyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008 Jul; 35(7): 807–11PubMed

185.

Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002 Feb 1; 51(3): 261–3PubMed

186.

Dolzan V, Plesnicar BK, Serretti A, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007 Sep 5; 144B(6): 809–15PubMed

187.

Mihara K, Suzuki A, Kondo T, et al. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. Am J Med Genet 2000 Jun 12; 96(3): 422–4PubMed

188.

Lattuada E, Cavallaro R, Serretti A, et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004 Dec; 7(4): 489–93PubMed

189.

Mihara K, Kondo T, Suzuki A, et al. No relationship between -141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Psychiatry Res 2001 Feb 14; 101(1): 33–8PubMed

190.

Chong SA, Tan EC, Tan CH, et al. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003 Jan 1; 116(1): 51–4

191.

Hori H, Ohmori O, Shinkai T, et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001 Dec 8; 105(8): 774–8PubMed

192.

Kaiser R, Tremblay PB, Klufmoller F, et al. Relationship between adverse effects of antipsychotic treatment and dopamine D-2 receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7(7): 695–705PubMed

193.

Liou YJ, Lai IC, Liao DL, et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 2006 Sep; 86(1–3): 323–5PubMed

194.

Al Hadithy AF, Wilffert B, Stewart RE, et al. Pharmaco-genetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008 Sep 5; 147B(6): 890–7

195.

Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2(2): 139–45PubMed

196.

Segman R, Neeman T, Herseco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247–53PubMed

197.

Rietschel M, Krauss H, Muller DJ, et al. Dopamine D3 receptor variant and tardive dyskinesia 1. Eur Arch Psychiatry Clin Neurosci 2000; 250(1): 31–5PubMed

198.

Garcia-Barcelo MM, Lam LC, Ungvari GS, et al. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001; 108(6): 671–7PubMed

199.

Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002 Jul; 27(1): 105–19PubMed

200.

Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44(2): 95–8PubMed

201.

Woo SI, Kim JW, Rha E, et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics 1. Psychiatry Clin Neurosci 2002 Aug; 56(4): 469–74PubMed

202.

Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen’s study on DRD3 and tardive dyskinesia. Am J Med Genet 2000; 96(2): 187–91PubMed

203.

Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet 2009 Apr; 19(2): 106–7PubMed

204.

Wilffert B, Al Hadithy AF, Sing VJ, et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009 Aug; 23(6): 652–9PubMed

205.

Mihara K, Kondo T, Higuchi H, et al. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002 Aug 8; 114(6): 693–5PubMed

206.

Zai CC, Tiwari AK, Basile V, et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J Jun; 9 (3): 168-74

207.

Lafuente A, Bernardo M, Mas S, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007 Feb; 90(1–3): 115–22PubMed

208.

Shinkai T, Muller DJ, De Luca V, et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res 2006 Feb 28; 141(2): 123–8PubMed

209.

Tan EC, Chong SA, Mahendran R, et al. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001 Jul 15; 50(2): 144–7PubMed

210.

Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001 Mar; 6(2): 225–9PubMed

211.

Lerer B, Segman RH, Tan EC, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005 Sep; 8(3): 411–25PubMed

212.

Deshpande SN, Varma PG, Semwal P, et al. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005 Sep; 15(3): 157–8PubMed

213.

Basile VS, Ozdemir V, Masellis M, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001 Mar; 6(2): 230–4PubMed

214.

Zhang ZJ, Zhang XB, Sha WW, et al. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7(7): 670–1PubMed

215.

Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000 Nov; 152(4): 408–13

216.

Rietschel M, Naber D, Fimmers R, et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1999; 8(8): 1999–2003

217.

Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 2002; 7(2): 137–9PubMed

218.

Ohmori O, Shinkai T, Hori H, et al. Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002 Jun 1; 110(2): 97–102PubMed

219.

Chong SA, Tan EC, Tan CH, et al. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 2000 Dec 4; 96(6): 712–5PubMed

220.

Kastelic M, Koprivsek J, Plesnicar BK, et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010 Mar 17; 34(2): 387–92PubMed

221.

Zhang Z, Zhang X, Hou G, et al. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002 Sep; 36(5): 317–24PubMed

222.

Pae CU, Kim TS, Patkar AA, et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res 2007 Sep 30; 153(1): 77–81PubMed

223.

Liu H, Wang C, Chen PH, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010 May 30; 34(4): 692–6PubMed

224.

Wang YC, Liou YJ, Liao DL, et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2004 May; 111(5): 623–9PubMed

225.

Shinkai T, Ohmori O, Matsumoto C, et al. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med 2004; 5(2): 163–70PubMed

226.

Liou YJ, Lai IC, Lin MW, et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics 2006 Mar; 16(3): 151–7PubMed

227.

Pae CU, Yu HS, Kim JJ, et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004 Dec; 7(4): 495–500PubMed

228.

Liou YJ, Wang YC, Lin CC, et al. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187-Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int J Neuropsychopharmacol 2005 Sep; 8(3): 483–6PubMed

229.

Greenbaum L, Strous RD, Kanyas K, et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007 Jul; 17(7): 519–28PubMed

230.

Greenbaum L, Smith RC, Rigbi A, et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region. Pharmaco-genomics J 2009 Apr; 9(2): 103–10

231.

Higa M, Ohnuma T, Maeshima H, et al. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett 2010 Jan 18; 469(1): 55–9PubMed

232.

de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005 Jan; 66(1): 15–27PubMed

233.

Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 2010 Jan; 14(3): 1–157, iiiPubMed

234.

Gasso P, Mas S, Crescenti A, et al. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. Psychiatry Res 2010 Jan 30; 175(1–2): 173–5PubMed

235.

Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007; 12(9): 794–5PubMed

236.

Bakker PR, van Harten PN, Van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006 Apr; 83(2–3): 185–92PubMed

237.

Srivastava V, Deshpande SN, Nimgaonkar VL, et al. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008 Aug; 9(8): 1055–68PubMed

238.

Shinkai T, De Luca V, Hwang R, et al. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neurosci Lett 2005 Nov 11; 388(2): 116–20PubMed

239.

Liu YR, Loh EW, Lan TH, et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010 Feb; 10(1): 30–9PubMed

240.

Wang YC, Bai YM, Chen JY, et al. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005 Nov; 112(11): 1463–8PubMed

241.

Sickert L, Muller DJ, Tiwari AK, et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009 Jul; 10(7): 1169–76PubMed

242.

Tsai SJ, Yu YW, Lin CH, et al. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50(1): 37–40PubMed

243.

Clark D, Skrobot OA, Adebiyi I, et al. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. Eur Psychiatry 2009 Oct; 24(7): 456–63PubMed

244.

Zhang XY, Zhou DF, Wu GY, et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008 Aug; 33(9): 2200–5PubMed

245.

Tiwari AK, Rodgers JB, Sicard M, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010 Dec 1; 34(8): 1484–90PubMed

246.

Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 2010 May; 35(6): 1315–24PubMed

247.

Ellingrod VL, Miller D, Schultz SK, et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002 Mar; 12(1): 55–8PubMed

248.

Zhang ZJ, Yao ZJ, Zhang XB, et al. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin 2003 Mar; 24(3): 235–40PubMed

249.

Popp J, Leucht S, Heres S, et al. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009 Feb; 9(1): 71–7PubMed

250.

Wang YC, Bai YM, Chen JY, et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005 Oct; 15(10): 743–8PubMed

251.

Bishop JR, Ellingrod VL, Moline J, et al. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006 Feb; 12(2): BR47–50PubMed

252.

Park YM, Chung YC, Lee SH, et al. G-protein beta3 sub-unit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig 2009 Mar; 6(1): 39–43PubMed

253.

Hong CJ, Lin CH, Yu YW, et al. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 2002 Sep; 12(3): 169–71PubMed

254.

Hong CJ, Lin CH, Yu YW, et al. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001 Apr; 11(3): 265–8PubMed

255.

Al-Janabi I, Arranz MJ, Blakemore AI, et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 2009 Dec; 19(6): 305–11PubMed

256.

Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009 Feb; 29(1): 65–8PubMed

257.

Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002 Jun 15; 359(9323): 2086–7PubMed

258.

Tsai SJ, Hong CJ, Yu YW, et al. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain [letter]. Lancet 2002 Nov 30; 360(9347): 1790PubMed

259.

Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62 Suppl. 23: 45–66PubMed

260.

Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 677–9PubMed

261.

Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5-HT2C receptor -759-C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133B(1): 97–100PubMed

262.

Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005 Apr; 15(4): 195–200PubMed

263.

Theisen FM, Hinney A, Bromel T, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004 Sep; 14(3): 139–42PubMed

264.

Ryu S, Cho EY, Park T, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13; 31(3): 673–7PubMed

265.

Park YM, Cho JH, Kang SG, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008 Feb; 33(1): 55–60PubMed

266.

Yevtushenko OO, Cooper SJ, O’Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008 Jun; 192(6): 424–8PubMed

267.

Kuzman MR, Medved V, Bozina N, et al. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008 Sep 30; 160(3): 308–15PubMed

268.

De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007 Oct; 10(5): 697–704PubMed

269.

Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 2007 Oct; 7(5): 318–24PubMed

270.

Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009 Feb; 29(1): 16–20PubMed

271.

Opgen-Rhein C, Brandl EJ, Muller DJ, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010 Jun; 11(6): 773–80PubMed

272.

Le HS, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry 2009 Mar; 14(3): 308–17

273.

Tiwari AK, Zai CC, Meltzer HY, et al. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol 2010 Apr; 25(3): 253–9PubMed

274.

Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007 Jun; 27(3): 246–51PubMed

275.

Kang SG, Lee HJ, Park YM, et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jan 1; 32(1): 160–3PubMed

276.

Gregoor JG, van der Weide J, Mulder H, et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2009 Feb; 29(1): 21–5PubMed

277.

Ellingrod VL, Miller DD, Taylor SF, et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008 Jan; 98(1–3): 47–54PubMed

278.

van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010 Aug; 121(1–3): 193–8PubMed

279.

Herken H, Erdal M, Aydin N, et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009 Oct; 28(10): 515–9PubMed

280.

Muller DJ, Klempan TA, De Luca V, et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005 May 6; 379(2): 81–9PubMed

281.

Musil R, Spellmann I, Riedel M, et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008 Oct; 42(12): 963–70PubMed

282.

Wang YC, Bai YM, Chen JY, et al. Genetic association between TNF-alpha −308 G>A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol 2010 Jun; 25(4): 303–9PubMed

283.

Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1* 0201. Int J Neuropsychopharmacol 1998; 1: 41–4PubMed

284.

Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulotycosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998; 25(1): 11–3PubMed

285.

Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001 Mar; 11(2): 135–41PubMed

286.

Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011 Apr; 72(4): 458–63PubMed

287.

Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004 Dec; 24(6): 613–7PubMed

288.

Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D 6. Pharmacopsychiatry 2000 Nov; 33(6): 218–20PubMed

289.

Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003 Dec; 62(6): 483–91PubMed

290.

Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapin-induced agranulocytosis in two different ethnic groups. Blood 1997; 89(11): 4167–74PubMed

291.

Chagnon YC, Merette C, Bouchard RH, et al. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004 Dec; 9(12): 1067–74PubMed

292.

Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008 Apr; 18(4): 317–23PubMed

293.

McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011 Jan; 16(1): 76–85PubMed

294.

McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011 Feb; 36(3): 616–26PubMed

295.

Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. Epub 2010 Oct 5

296.

Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011 Mar; 16(3): 321–32PubMed

297.

Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009 Oct; 206(3): 491–9

298.

Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009 Aug; 14(8): 804–19PubMed

299.

Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009 Nov; 14(11): 1024–31PubMed

300.

Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010 Feb 1; 67(3): 263–9PubMed

Titel: Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia
verfasst von: Dr Maria J. Arranz
Margarita Rivera
Janet C. Munro
Publikationsdatum: 01.11.2011
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11595380-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2011

The Hippocampus, Neurotrophic Factors and Depression

Needle-Free Subcutaneous Sumatriptan

Erratum to: Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder: Current Status of Knowledge

The Pharmacology of New Antiepileptic Drugs